INVESTORS

Investor Relations

Recent News
Dec 3, 2018

- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks - - Data from...

Nov 29, 2018

- SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC) – - Activates immune signaling STING pathway - - Data reported at the AACR Conference on Tumor Immunology and...

Nov 27, 2018

- Call to include Dr. Srdan Verstovsek and will discuss emerging clinical data demonstrating momelotinib's unique anemia benefit in patients with myelofibrosis - VANCOUVER, Nov. 27, 2018 /CNW/ -...

View all news releases

Events and Webcasts
Monday, December 3, 2018
4:30pm EST

Dial-in Details:
Domestic (Toll Free- US): 1-800-289-0438
International (Toll): 1-323-794-2423
Conference ID: 6168197

 

View all events and webcasts

Investor Enquiries

James Smith, Vice President Corporate Affairs
investors@sierraoncology.com

Sign up for investor alerts